IndraLab
Statements
sparser
"MCL1 WT and S159D mutant (which is a phosphomimetic mutant in the GSK3β phosphorylation site), but not MCL1 S159A mutant (which abolished phosphorylation by GSK-3), substantially decreased the interaction between JOSD1 and MCL-1 in the presence of IR in CAL27R cells (Fig. xref )."
reach
"TRAF4 promoted Akt K63-linked ubiquitination and activation to suppress GSK3β activity and MCL-1 S159 phosphorylation, facilitating the interaction between MCL-1 and JOSD1, which ultimately promoted the stability and expression of MCL-1 to confer resistance to radiotherapy in OSCC cells (Fig. 7G)."
sparser
"TRAF4 promoted Akt K63-linked ubiquitination and activation to suppress GSK3β activity and MCL-1 S159 phosphorylation, facilitating the interaction between MCL-1 and JOSD1, which ultimately promoted the stability and expression of MCL-1 to confer resistance to radiotherapy in OSCC cells (Fig. xref )."
JOSD1 affects apoptotic process
|
10
JOSD1 inhibits apoptotic process.
|
6
JOSD1 activates apoptotic process.
|
4
JOSD1 activates apoptotic process. 4 / 4
|
4
reach
"We found that ATXN3 inhibited apoptosis, while JOSD1 and JOSD2 promoted apoptosis, JOSD2 inhibited DNA damage response, JOSD1 and JOSD2 promoted EMT, and JOSD2 suppressed RTK and androgen pathways.Moreover, we used the cBioPortal database to explore the co-expression (Table 3) and mutual exclusion (Table 4) between individual members of the MJDs family."
JOSD1 is modified
|
6
reach
"On this basis, overexpression of JOSD2, not JOSD1, dramatically decreased the polyubiquitin chains of KRAS promoted by LZTR1 and restored the LZTR1-mediated KRAS levels downregulation (Fig. 2k and Supplementary Fig. 2k, l), indicating that JOSD2 reversed the effect of LZTR1-mediated KRAS ubiquitination degradation."
reach
"Besides, we found that knockdown of BRD4 by shRNA, resembling the effect of JQ1, inhibited the expression of JOSD1 (Fig. 2e, f), while BRD4 overexpression significantly upregulated JOSD1 in HNSCC cells (Fig. 2g, h), suggesting that BRD4 affected JOSD1 expression at the transcriptional level."
reach
"Besides, we found that knockdown of BRD4 by shRNA, resembling the effect of JQ1, inhibited the expression of JOSD1 (Fig. 2e, f), while BRD4 overexpression significantly upregulated JOSD1 in HNSCC cells (Fig. 2g, h), suggesting that BRD4 affected JOSD1 expression at the transcriptional level."
JOSD1 affects cell population proliferation
|
4
JOSD1 activates cell population proliferation.
|
3
JOSD1 inhibits cell population proliferation.
|
1
JOSD1 inhibits cell population proliferation. 1 / 1
|
1
JOSD1 affects HNSCC
|
4
JOSD1 affects tumor growth
|
3
JOSD1 affects cell death
|
3
JOSD1 activates cell death.
|
2
JOSD1 activates cell death. 2 / 2
|
2
reach
"We found that overexpression of SOCS1 caused a decrease in CC3 expression and number of dead cells (Supplementary Fig 3A–C), while its downregulation conversely caused an increase in CC3 expression (Fig. 5A) and number of dead cells (Fig. 5B) under proteasomal inhibition in a manner similar to JOSD1.Next, we sought to determine whether SOCS1 sufficiency was a prerequisite for JOSD1’s ability to modulate cell death under proteotoxic conditions."
JOSD1 inhibits cell death.
|
1
JOSD1 inhibits cell death. 1 / 1
|
1
JOSD1 affects JAK2-V617F
|
3
JOSD1 affects defense response to virus
|
2
JOSD1 affects cell motility
|
1
JOSD1 activates cell motility. 1 / 2
|
1
JOSD1 affects cell growth
|
1
1
JOSD1 increases the amount of JOSD1.
|
1
reach
"Jing et al. found that under epigenetic regulation of BRD4, JOSD1 was overexpressed in HNSCC, and increased expression of JOSD1 was positively correlated with proliferation and chemoresistance of HNSCC cells, while highly expressed JOSD1 was also associated with poor prognosis of HNSCC patients [42]."
JOSD1 activates JOSD1.
|
1
sparser
"Subsequently, we examined the biological activity of GST-JOSD2/JOSD1 by introducing their co-reported substrate proteins YAP xref , xref , as shown in Supplementary Fig. xref , both GST-JOSD2 and GST-JOSD1 efficiently removing the polyubiquitin chains of YAP, confirming that our purified recombinant protein are biologically active."
sparser
"More importantly, we performed in vitro deubiquitination assays using bacterial-expressed recombinant rhJOSD2 and found rhJOSD2 effectively removing the polyubiquitin chains of KRAS wild-type and mutants, while GST-JOSD1 failed to pose similar effects (Fig. xref and Supplementary Fig. xref )."
sparser
"Subsequently, we examined the biological activity of GST-JOSD2/JOSD1 by introducing their co-reported substrate proteins YAP xref , xref , as shown in Supplementary Fig. xref , both GST-JOSD2 and GST-JOSD1 efficiently removing the polyubiquitin chains of YAP, confirming that our purified recombinant protein are biologically active."
sparser
"More importantly, we performed in vitro deubiquitination assays using bacterial-expressed recombinant rhJOSD2 and found rhJOSD2 effectively removing the polyubiquitin chains of KRAS wild-type and mutants, while GST-JOSD1 failed to pose similar effects (Fig. xref and Supplementary Fig. xref )."
|
1
|
1
Facilitating transcription activation affects JOSD1
|
1
Epigenetic regulator BRD4 affects JOSD1
|
1
Administration JQ1 cells affects JOSD1
|
1
XMU-MP-1 affects JOSD1
|
1
USP21c affects JOSD1
|
1
JOSD1 affects tumor cell
|
1
JOSD1 affects tumor cell invasion
|
1
|
1
|
1
JOSD1 affects signal transduction
|
1
JOSD1 inhibits signal transduction. 1 / 1
|
1
JOSD1 affects signal cascade
|
1
JOSD1 affects plasma membrane
|
1
JOSD1 inhibits plasma membrane. 1 / 1
|
1
JOSD1 affects pathway
|
1
JOSD1 affects metastasis dependence Snail
|
1
JOSD1 affects localization
|
1
JOSD1 activates localization. 1 / 1
|
1
JOSD1 affects growth colony TSCCA SCC25 cells
|
1
|
1
JOSD1 activates epithelial to mesenchymal transition. 1 / 1
|
1
reach
"We found that ATXN3 inhibited apoptosis, while JOSD1 and JOSD2 promoted apoptosis, JOSD2 inhibited DNA damage response, JOSD1 and JOSD2 promoted EMT, and JOSD2 suppressed RTK and androgen pathways.Moreover, we used the cBioPortal database to explore the co-expression (Table 3) and mutual exclusion (Table 4) between individual members of the MJDs family."
JOSD1 affects cisplatin-induced apoptosis HNSCC cells
|
1
JOSD1 affects chemosensitivity HNSCC cells
|
1
JOSD1 affects chemoresistance
|
1
JOSD1 affects chemoresistance head neck squamous cell carcinoma epigenetic regulation enzymes
|
1
JOSD1 affects cell apoptosis
|
1
JOSD1 affects capacity colony
|
1
JOSD1 affects apoptosis-related proteins
|
1
JOSD1 affects apoptosis HNSCC cells treated CDDP flow cytometry
|
1
JOSD1 affects acquired chemoresistance
|
1
|
1
JOSD1 activates Squamous Cell Carcinoma of Head and Neck. 1 / 1
|
1
JOSD1 affects Reactive Oxygen Species
|
1
JOSD1 inhibits Reactive Oxygen Species. 1 / 1
|
1
JOSD1 affects Neoplasm Metastasis
|
1
JOSD1 activates Neoplasm Metastasis. 1 / 1
|
1
JOSD1 affects Leukemia, Myeloid, Acute
|
1
JOSD1 inhibits Leukemia, Myeloid, Acute. 1 / 1
|
1
JOSD1 affects Hippo
|
1
JOSD1 affects HNSCC cell
|
1
JOSD1 affects Carcinogenesis
|
1
JOSD1 activates Carcinogenesis. 1 / 1
|
1
JOSD1 affects CDDP treating HNSCC
|
1
JAK2-V617F affects JOSD1
|
1
BRD4 shRNA resembling JQ1 affects JOSD1
|
1
eidos
"Besides , we found that knockdown of BRD4 by shRNA , resembling the effect of JQ1 , inhibited the expression of JOSD1 ( Fig. 2e , f ) , while BRD4 overexpression significantly upregulated JOSD1 in HNSCC cells ( Fig. 2g , h ) , suggesting that BRD4 affected JOSD1 expression at the transcriptional level ."
BRD4 overexpression affects JOSD1
|
1
eidos
"Besides , we found that knockdown of BRD4 by shRNA , resembling the effect of JQ1 , inhibited the expression of JOSD1 ( Fig. 2e , f ) , while BRD4 overexpression significantly upregulated JOSD1 in HNSCC cells ( Fig. 2g , h ) , suggesting that BRD4 affected JOSD1 expression at the transcriptional level ."